BioStem Technologies Q1 revenue falls 62% yr/yr

BioStem Technologies

14/05/2026 21:25

Overview

Regenerative medicine firm's Q1 revenue fell sharply yr/yr after BioTissue asset acquisition

Company posted Q1 net loss versus net income a year earlier

Revenue and margin declines driven by product mix and integration of acquired assets

Outlook

BioStem expects 2026 revenue between $25 mln and $29 mln

Company anticipates sequential hospital business growth in H2 2026

BioStem expects sequential physician office revenue growth in H2 2026

Result Drivers

PRODUCT MIX SHIFT - Gross margin declined due to increased sales of Neox and Clarix products, which are subject to cost-plus markup under the current manufacturing supply agreement

HOSPITAL FOCUS - Revenue was primarily driven by hospital-based sales, reflecting the company's strategic shift following the BioTissue asset acquisition

INTEGRATION COSTS - Operating expenses included costs related to the BioTissue assets transaction and uplist process, partly offset by the absence of prior quarter's bad debt expense

Company press release: ID:nGNX7CcWHx

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$6.10 mln
$5.70 mln (1 Analyst)
Q1 EPS
Miss
-$0.52
-$0.28 (1 Analyst)

Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Biostem Technologies Inc is $9.00, about 77.3% above its May 13 closing price of $5.08

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)